Intraocular Pressure and Ocular Hypertension

Primary open-angle glaucoma (POAG) is a multi-factorial progressive optic neuropathy characterized by retinal ganglion cell degeneration and progressive visual field loss which, if left untreated, may lead to blindness. Increased intraocular pressure (IOP) is considered to be the main risk factor fo...

Full description

Saved in:
Bibliographic Details
Other Authors: Brusini, Paolo (Editor), Salvetat, Maria Letizia (Editor), Zeppieri, Marco (Editor)
Format: Electronic Book Chapter
Language:English
Published: Basel 2022
Subjects:
age
ORA
n/a
Online Access:DOAB: download the publication
DOAB: description of the publication
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000naaaa2200000uu 4500
001 doab_20_500_12854_92136
005 20220916
003 oapen
006 m o d
007 cr|mn|---annan
008 20220916s2022 xx |||||o ||| 0|eng d
020 |a books978-3-0365-5099-2 
020 |a 9783036551005 
020 |a 9783036550992 
040 |a oapen  |c oapen 
024 7 |a 10.3390/books978-3-0365-5099-2  |c doi 
041 0 |a eng 
042 |a dc 
072 7 |a M  |2 bicssc 
100 1 |a Brusini, Paolo  |4 edt 
700 1 |a Salvetat, Maria Letizia  |4 edt 
700 1 |a Zeppieri, Marco  |4 edt 
700 1 |a Brusini, Paolo  |4 oth 
700 1 |a Salvetat, Maria Letizia  |4 oth 
700 1 |a Zeppieri, Marco  |4 oth 
245 1 0 |a Intraocular Pressure and Ocular Hypertension 
260 |a Basel  |c 2022 
300 |a 1 electronic resource (288 p.) 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
506 0 |a Open Access  |2 star  |f Unrestricted online access 
520 |a Primary open-angle glaucoma (POAG) is a multi-factorial progressive optic neuropathy characterized by retinal ganglion cell degeneration and progressive visual field loss which, if left untreated, may lead to blindness. Increased intraocular pressure (IOP) is considered to be the main risk factor for developing POAG, and its reduction has been shown to correlate with a decrease in glaucoma incidence and progression. Considering that fewer than 10% of the subjects with ocular hypertension (OHT) will develop morphological and/or functional glaucomatous damage within 5 years if not treated, glaucoma causes and molecular changes leading to ocular tissue damage in glaucoma are still largely unknown. The contemporary treatment of POAG is mainly oriented towards reducing IOP; the importance of the IOP reduction in other types of glaucoma, such as the "normal pressure glaucoma", is still discussed. The IOP value is maintained by balancing the amount of fluid contained within the anterior and posterior chambers of the eye; our comprehension of the mechanisms underlying the secretion and active and passive outflow of the aqueous humor is extremely important for improving the treatment of glaucoma. Innovative pharmacological approaches, and laser and surgical procedures aiming to reduce IOP, have been developed in recent years. This book provides a compendium of topics regarding IOP, aqueous humor dynamics, tonometry, and medical and surgical techniques developed to reduce the IOP in subjects with ocular hypertension or glaucoma. 
540 |a Creative Commons  |f https://creativecommons.org/licenses/by/4.0/  |2 cc  |4 https://creativecommons.org/licenses/by/4.0/ 
546 |a English 
650 7 |a Medicine  |2 bicssc 
653 |a intraocular pressure 
653 |a serum calcium 
653 |a female 
653 |a ab interno trabeculotomy 
653 |a glaucoma 
653 |a incision in the Schlemm's canal in degrees 
653 |a post-surgical complication 
653 |a neuroretinal rim reversal 
653 |a Bruch's membrane opening-minimum rim width 
653 |a trabeculectomy 
653 |a refractive error 
653 |a neuroretina 
653 |a myopia 
653 |a intraocular pressure (IOP) 
653 |a tonometry 
653 |a Goldmann applanation tonometer (GAT) 
653 |a central corneal thickness (CCT) 
653 |a ocular hypertension 
653 |a higher-order aberrations 
653 |a Kahook Dual Blade 
653 |a age 
653 |a central corneal thickness 
653 |a Goldmann Applanation tonometer 
653 |a non-contact tonometer 
653 |a rebound tonometer 
653 |a iCare 
653 |a open angle glaucoma (OAG) 
653 |a Schlemm's canal viscodilation 
653 |a OMNI viscosurgical system 
653 |a minimally invasive glaucoma surgeries (MIGS) 
653 |a trabeculotomy 
653 |a cataract extraction 
653 |a aqueous humor 
653 |a GDF15 
653 |a serum 
653 |a intravitreal injection 
653 |a anti-VEGF agents 
653 |a trabecular meshwork 
653 |a Matrigel 
653 |a 3D culture 
653 |a outflow 
653 |a cytoskeleton 
653 |a rho-kinase inhibitor 
653 |a prostaglandin analog 
653 |a childhood glaucoma 
653 |a aphakia 
653 |a pseudophakia 
653 |a cataract surgery 
653 |a lensectomy 
653 |a management (or therapy) 
653 |a glaucoma drainage device 
653 |a cyclodestruction 
653 |a corneal biomechanics 
653 |a ocular response analyzer 
653 |a ORA 
653 |a corneal hysteresis 
653 |a non-penetrating deep sclerectomy 
653 |a Esnoper V-2000 implant 
653 |a glucocorticoids 
653 |a safety profile 
653 |a intranasal administration 
653 |a inhaled administration 
653 |a systemic administration 
653 |a steroid response 
653 |a canaloplasty 
653 |a non-perforating surgical procedures 
653 |a pseudoexfoliation glaucoma (PEXG) 
653 |a Schlemm's canal 
653 |a phase-sensitive optical coherent tomography 
653 |a pulsatile motion 
653 |a IOP fluctuation 
653 |a primary open-angle glaucoma 
653 |a intraocular pressure measurement 
653 |a iCare tonometry 
653 |a Perkins tonometry 
653 |a standardized anaesthesia 
653 |a corneal thickness 
653 |a progression 
653 |a risk stratification 
653 |a XEN GelStent 
653 |a corneal resistance factor 
653 |a open-angle glaucoma 
653 |a n/a 
653 |a laser treatment 
653 |a dropless treatment 
653 |a thyroid-associated ophthalmopathy 
653 |a extraocular muscle 
653 |a magnetic resonance imaging 
653 |a T2 relaxation time 
856 4 0 |a www.oapen.org  |u https://mdpi.com/books/pdfview/book/6013  |7 0  |z DOAB: download the publication 
856 4 0 |a www.oapen.org  |u https://directory.doabooks.org/handle/20.500.12854/92136  |7 0  |z DOAB: description of the publication